BioCentury | Mar 13, 2021
Product Development

Long COVID therapies are starting to populate a sparse pipeline

...treat ME/CSF, and the If channel inhibitor Corlanor ivabradine...
...University of California San Diego who studied Corlanor...
BioCentury | Oct 3, 2017
Distillery Therapeutics

Neurology

...in diabetic neuropathy. In a mouse model of diabetic neuropathy, the HCN channel inhibitor Corlanor ivabradine...
...pain associated with diabetic neuropathy. Servier , Amgen Inc. and Ono Pharmaceutical Co. Ltd. market Corlanor...
BioCentury | Jan 11, 2016
Finance

Sowing season

...Inc. (NASDAQ:AMGN) Imlygic talimogene laherparepvec Melanoma EU / U.S. Amgen Inc. (NASDAQ:AMGN) / Servier Corlanor ivabradine...
BioCentury | Nov 16, 2015
Product Development

Myo my

...how they would account for the recent approvals of new drugs including Amgen's own Corlanor ivabradine...
...any safety signals that would preclude adding omecamtiv mecarbil onto SOC, or onto Entresto or Corlanor...
...with sacubitril, an inhibitor of neutral endopeptidase ( neprilysin ; MME ; NEP; CD10 ). Corlanor...
BioCentury | Apr 27, 2015
Strategy

Amgen's heart start

...Amgen Inc .'s new heart failure drug Corlanor ivabradine, the company's first CV product, will serve...
...as a launchpad for its other cardiovascular candidates, including PCSK9 inhibitor Repatha evolocumab. FDA approved Corlanor...
...a resting heart rate of at least 70 bpm or have contraindications to beta blockers. Corlanor...
BioCentury | Apr 22, 2015
Top Story

Amgen boosts revenue guidance ahead of Repatha

...Amgen's 1Q15 earnings call Tuesday that this month's launch of chronic heart failure drug Corlanor ivabradine...
...market ahead of its anticipated launch of Repatha evolocumab to treat high cholesterol. FDA approved Corlanor...
BioCentury | Apr 20, 2015
Clinical News

Procoralan ivabradine regulatory update

...FDA approved an NDA from Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.) for Corlanor ivabradine to treat...
...channel inhibitor within 1 week at a wholesale acquisition price of $375 per month. Specifically, Corlanor...
...Japan Servier , Neuilly-sur-Seine, France Product: Procoralan ivabradine ( Corlanor ) ( ONO-1162 ) (formerly (S-16257)...
BioCentury | Apr 16, 2015
Company News

FDA approves Amgen's Corlanor for heart failure

...FDA granted marketing approval for Corlanor ivabradine from Amgen Inc. (NASDAQ:AMGN) to treat chronic heart failure...
...price of $375 per month. Corlanor had Fast Track designation and was under Priority Review. Corlanor...
...beta blockers or have a contraindication to beta blocker use. The drug is marketed as Procoralan...
BioCentury | Dec 15, 2014
Clinical News

Procoralan ivabradine regulatory update

...patients receiving Corlentor /Procoralan ivabradine to treat angina and heart failure (HF). CHMP recommends that ivabradine...
...Servier markets Procoralan in at least 100 countries to treat stable angina and chronic HF. Procoralan...
...Ltd. (Tokyo:4528), Osaka, Japan Servier , Neuilly-sur-Seine, France Product: Procoralan ivabradine ( ONO-1162 ) (formerly (S-16257)...
BioCentury | Nov 24, 2014
Clinical News

Procoralan ivabradine regulatory update

...EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) recommended that patients taking Corlentor /Procoralan ivabradine should be monitored...
...are at an increased risk of developing atrial fibrillation (AF). The PRAC also recommended that Procoralan...
...Ltd. (Tokyo:4528), Osaka, Japan Servier , Neuilly-sur-Seine, France Product: Procoralan ivabradine ( ONO-1162 ) (formerly (S-16257)...
Items per page:
1 - 10 of 40